首页> 美国卫生研究院文献>other >Response to the U.S. FDA LeadCare Testing Systems Recall and CDC Health Alert
【2h】

Response to the U.S. FDA LeadCare Testing Systems Recall and CDC Health Alert

机译:对美国FDA LeadCare测试系统召回和CDC健康警报的响应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

On May 17, 2017, the Food and Drug Administration (FDA) issued a safety recall for the Magellan Diagnostics’ LeadCare Testing Systems due to the potential for inaccurately low blood lead test results when used with venous blood samples, which has implications for the follow-up care of persons exposed to lead. Concurrent with the recall, the Centers for Disease Control and Prevention (CDC) issued a health alert regarding the use of LeadCare Testing Systems. CDC provided recommendations for specific high-risk populations so that persons potentially impacted by falsely low test results could be retested and receive appropriate follow-up care. Childhood lead poisoning prevention programs in state and local public health agencies collect blood lead test results for children and had a lead role in identifying children for retesting. CDC’s Lead Poisoning Prevention Program sought to understand how the recall and recommendations impacted state and local public health agencies. Case studies are presented that highlight the experiences of four state childhood lead poisoning prevention programs in responding to the recall and recommendations. Collectively, the case studies point to several lessons learned, including the importance of: (1) having a well-functioning surveillance system in place prior to a serious incident; (2) having a clear understanding of the roles partners play in the continuum of care for children potentially exposed to lead; (3) ensuring effective communications with all staff, both internal and external, to public health agencies that have a role in responding to a serious incident. The ability to respond to public health emergencies or other serious incidents takes the combined effort of federal, state, and local public health agencies as well as others in the healthcare delivery system. CDC will continue to support state and local lead poisoning prevention programs so they have the information and tools they need to address and prevent the health effects of lead exposures in communities.
机译:2017年5月17日,美国食品药品监督管理局(FDA)对Magellan Diagnostics的LeadCare检测系统发出了安全召回通知,原因是与静脉血样本一起使用时,低铅检测结果可能不准确,这可能导致以下情况铅接触者的特写护理。在召回的同时,疾病控制与预防中心(CDC)发布了有关LeadCare测试系统使用情况的健康警报。美国疾病预防控制中心(CDC)为特定的高危人群提供了建议,以便对可能受到错误低的检测结果影响的人进行重新检测,并接受适当的后续护理。州和地方公共卫生机构的儿童铅中毒预防计划收集了儿童的血液铅测试结果,并在识别儿童进行重新测试方面发挥了领导作用。 CDC的预防铅中毒计划旨在了解召回和建议如何影响州和地方公共卫生机构。案例研究重点介绍了四个州儿童期铅中毒预防计划在应对召回和建议方面的经验。总体而言,案例研究指出了一些经验教训,包括以下方面的重要性:(1)在发生严重事件之前建立功能完善的监视系统; (2)清楚了解伴侣在连续照顾可能接触铅的儿童中扮演的角色; (3)确保与负责应对严重事件的公共卫生机构的所有内部和外部人员进行有效沟通。应对突发公共卫生事件或其他严重事件的能力需要联邦,州和地方公共卫生机构以及医疗保健提供系统中的其他机构共同努力。疾病预防控制中心将继续支持州和地方的铅中毒预防计划,以便他们拥有解决和预防社区铅暴露对健康的影响所需的信息和工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号